Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis

Sanyal, A.; Anstee, Quentin M.; Brass, C.; Agashivala, Neetu; Collen, Rebeca; Langford, Aisha T.; Cryer, Donna; Slota, Christina; Twiss, John Russell; Balp, Maria‐Magdalena; Doward, Lynda

doi:10.1016/s0168-8278(18)31397-7

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instruments assessing general health-related quality of life (HRQoL) questionnaires such as the Short Form-36 (SF-36), EuroQoL 5-Dimensions 5-Level (EQ-5D-5L), the Chronic Liver Disease Questionnaire (CLDQ) and more recently, disease-specific questionnaires such as CLDQ-NASH and NASH-CHECK have been validated in MAFLD [266][267][268]. These questionnaires have been translated into various languages and validated internationally.…”

Section: Patient-reported Outcomes In Mafldmentioning

confidence: 99%

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

et al. 2020

View full text Add to dashboard Cite

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its Electronic supplementary material The online version of this article (

show abstract

Section: Patient-reported Outcomes In Mafldmentioning

confidence: 99%

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[ 149 150 ] Instruments for assessing patient reported outcomes (PRO) include questionnaires that evaluate general HRQoL such as Chronic Liver Disease Questionnaire (CLDQ), the Short Form-36 (SF-36), and EuroQoL 5-Dimensions 5-Level (EQ-5D-5L), or disease-specific questionnaires such as NASH-CHECK and CLDQ-NASH. [ 151 152 153 ] Although these questionnaires have been translated into various languages and validated in various countries, these are yet to be well validated in Egypt, and how cultural variation may influence the PROs is not known.…”

Section: Patient Reported Outcomes In Mafldmentioning

confidence: 99%

The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Fouad

Esmat

Elwakil

et al. 2022

Saudi J Gastroenterol

View full text Add to dashboard Cite

The landscape of chronic liver disease in Egypt has drastically changed over the past few decades. The prevalence of metabolic-associated fatty liver disease (MAFLD) has risen to alarming levels. Despite the magnitude of the problem, no regional guidelines have been developed to tackle this disease. This document provides the clinical practice guidelines of the key Egyptian opinion leaders on MAFLD screening, diagnosis, and management, and covers various aspects in the management of MAFLD. The document considers our local situations and the burden of clinical management for the healthcare sector and is proposed for daily clinical practical use. Particular reference to special groups was done whenever necessary.

show abstract

“…Patients will also be asked to rate the severity of symptoms over the past 7 days as 'no symptoms', 'very mild', 'mild', 'moderate', 'severe', or 'very severe'. NASH-CHECK, a self-reported disease-specific PRO questionnaire [38], will assess the health-related quality of life of patients. In addition, patients will also be asked to rate the overall impact of NASH on their lives at Week 48 on the following categories: 'a great deal worse', 'moderately worse', 'a little worse', 'about the same', 'a little better', 'moderately better' or 'a great deal better'.…”

Section: Other Assessmentsmentioning

confidence: 99%

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

Pedrosa

Seyedkazemi

Francque

et al. 2020

Contemporary Clinical Trials

View full text Add to dashboard Cite

Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis

Cited by 4 publications

References 0 publications

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

Contact Info

Product

Resources

About